✦ LIBER ✦

212 POSTER A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib

✍ Scribed by A.J. Wagner; S. Yazji; J.A. Morgan; E. Choy; S. George; M. Hohos; M. O'Mara; G.D. Demetri

Book ID: 119599367
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 59 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)72144-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

7511 POSTER Safety and efficacy results

7511 POSTER Safety and efficacy results of sunitinib from a worldwide treatment- use trial of gastrointestinal stromal tumour (GIST) patients (pts) with resistance or intolerance to prior imatinib therapy

✍ Seddon, B.; Reichardt, P.; Ruka, W.; Kang, Y.K.; Baum, C.M.; Demetri, G.D. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Pilot study of lonafarnib, a farnesyl tr

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

✍ Gautam Borthakur; Hagop Kantarjian; George Daley; Moshe Talpaz; Susan O'Brien; G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

344 POSTER A phase Ib dose escalation st

344 POSTER A phase Ib dose escalation study to evaluate safety and tolerability of the combination of the aminopeptidase inhibitor CHR-2797 and paclitaxel in patients with advanced or treatment refractory tumors

✍ C. van Herpen; F. Eskens; M. de Jonge; I. Desar; L. Hooftman; E. Bone; A. Timmer 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Use of c-KIT/PDGFRA mutational analysis

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

✍ M. Debiec-Rychter; H. Dumez; I. Judson; B. Wasag; J. Verweij; M. Brown; S. Dimit 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 309 KB

414 POSTER A phase I, open-label, dose e

414 POSTER A phase I, open-label, dose escalation study of the humanized monoclonal antibody (HuMAb) TRC093, an inhibitor of angiogenesis that binds to cleaved collagen, in patients with locally advanced or metastatic solid tumors

✍ M.S. Gordon; L.S. Rosen; F. Robert; D.S. Mendelson; D. Kleinzweig; B.J. Adams; C 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB

411 POSTER A phase I, open-label, dose-e

411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors

✍ R. Salgia; A. Peterson; S. Eppler; W. Yu; B. Polite; D. Geary; E. Wesolowski; M. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB